FDA Moves Ahead With Third-Party 510(k) Review
Executive Summary
A new guidance document from the US FDA discusses how the agency will accredit and oversee third-party reviewers, as well as how it will determine which 510(k) devices are eligible for outside review.
You may also be interested in...
Lifting The Hood On MDUFA V
The document includes promises from the US FDA related to review timelines, consensus standards, the Total Product Life Cycle pilot, and more.
Third-Party Review: FDA Seeks Tangible 510(k) Results Over Next Three Years
Under a new plan and draft guidance issued by US FDA, the agency is hoping to streamline and improve its third-party review program. The goal is to spend substantially less FDA resources re-reviewing low-to-moderate risk 510(k) applications that go through the program and allow products to enter market sooner.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.